Seres Therapeutics Inc Share Price Today: Live Updates & Key Insights

Seres Therapeutics Inc share price today is $8.67, up -6.39%. The stock opened at $8.65 against the previous close of $9.08, with an intraday high of $8.89 and low of $8.44.

Seres Therapeutics Inc Share Price Chart

Seres Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Seres Therapeutics Inc Share Price Performance

$8.67 -0.0639(-6.39%) MCRB at 23 Mar 2026 02:13 PM Biotechnology
Lowest Today 8.44
Highest Today 8.89
Today’s Open 8.65
Prev. Close 9.08
52 Week High 29.98
52 Week Low 6.53
Day’s Range: Low 8.44 High 8.89
52-Week Range: Low 6.53 High 29.98
1 day return -
1 Week return -2.31
1 month return +3.3
3 month return -42.12
6 month return -48.72
1 year return +1073.77
3 year return +44.44
5 year return -61.45
10 year return -

Seres Therapeutics Inc Institutional Holdings

Flagship Ventures Management, Inc. 12.10

Vanguard Group Inc 3.39

Vanguard Total Stock Mkt Idx Inv 2.16

Susquehanna International Group, LLP 1.88

Marshall Wace Asset Management Ltd 1.26

Vontobel Holding Ltd. 1.08

BlackRock Inc 1.07

Geode Capital Management, LLC 0.90

Vanguard Institutional Extnd Mkt Idx Tr 0.73

Avantis US Small Cap Value ETF 0.59

683 Capital Management LLC 0.55

LUX IM Global Medtech HX 0.40

Fidelity Extended Market Index 0.37

Schwab US Small-Cap ETF™ 0.33

Citadel Advisors Llc 0.33

Charles Schwab Investment Management Inc 0.33

State Street Corp 0.31

Schonfeld Strategic Advisors LLC 0.30

Lion Point Capital, LP 0.28

Two Sigma Investments LLC 0.27

Morgan Stanley - Brokerage Accounts 0.19

Blackrock Extended Mkt Fund CF 0.18

iShares Micro-Cap ETF 0.18

American Century Companies Inc 0.17

Extended Equity Market Fund K 0.15

Invesco RAFI US 1500 Small-Mid ETF 0.15

Omers Administration Corp 0.15

Fidelity Total Market Index 0.15

UBS Group AG 0.13

Northern Trust Corp 0.13

Amvescap Plc. 0.11

Fidelity Series Total Market Index 0.11

Spartan Extended Market Index Pool F 0.10

NT Ext Equity Mkt Idx Fd - L 0.08

DFA US Micro Cap I 0.08

Bridgeway Ultra-Small Company Market 0.08

WisdomTree US SmallCap Earnings ETF 0.08

NT Ext Equity Mkt Idx Fd - NL 0.07

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

Avantis US Small Cap Equity ETF 0.06

Seres Therapeutics Inc Market Status

Strong Buy: 2

Buy: 0

Hold: 2

Sell: 1

Strong Sell: 0

Seres Therapeutics Inc Fundamentals

Market Cap 76.90 M

PB Ratio 1.7639

PE Ratio 9.6591

Enterprise Value 114.69 M

Total Assets 138.19 M

Volume 84803

Seres Therapeutics Inc Company Financials

Annual Revenue FY23:127236000 127.2M, FY22:7128000 7.1M, FY21:144927000 144.9M, FY20:33215000 33.2M, FY19:34505000 34.5M

Annual Profit FY23:null 0.0M, FY22:6124000 6.1M, FY21:143195000 143.2M, FY20:33215000 33.2M, FY19:34505000 34.5M

Annual Net worth FY23:-141272000 -141.3M, FY22:-253824000 -253.8M, FY21:-61496000 -61.5M, FY20:-86454000 -86.5M, FY19:-64244000 -64.2M

Quarterly Revenue Q3/2025:351000 0.4M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-13001000 -13.0M, Q2/2025:-1059000 -1.1M, Q1/2025:-3527000 -3.5M, Q3/2024:null 0.0M, Q2/2024:-1420000 -1.4M

Quarterly Net worth Q3/2025:8204000 8.2M, Q2/2025:-19855000 -19.9M, Q1/2025:32682000 32.7M, Q3/2024:88776000 88.8M, Q2/2024:-32869999 -32.9M

About Seres Therapeutics Inc & investment objective

Company Information Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 66

Industry Biotechnology

CEO Mr. Richard N. Kender B.S., M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Seres Therapeutics Inc FAQs

What is the share price of Seres Therapeutics Inc today?

The current share price of Seres Therapeutics Inc is $8.67.

Can I buy Seres Therapeutics Inc shares in India?

Yes, Indian investors can buy Seres Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Seres Therapeutics Inc shares in India?

You can easily invest in Seres Therapeutics Inc shares from India by:

Can I buy fractional shares of Seres Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Seres Therapeutics Inc?

Seres Therapeutics Inc has a market cap of $76.90 M.

In which sector does Seres Therapeutics Inc belong?

Seres Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Seres Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Seres Therapeutics Inc?

The PE ratio of Seres Therapeutics Inc is 9.66 and the PB ratio is 1.76.